Feasibility Pilot Study of OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Jun 2019
Price : $35 *
At a glance
- Drugs Disufenton (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- 25 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 25 Sep 2018 Status changed from not yet recruiting to recruiting.
- 27 Aug 2018 Planned initiation date changed from 30 Jul 2018 to 1 Oct 2018.